Gary P Kobinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7473979/publications.pdf

Version: 2024-02-01

47006 40979 9,810 142 47 93 citations h-index g-index papers 146 146 146 13398 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	COVID-19: towards controlling of a pandemic. Lancet, The, 2020, 395, 1015-1018.	13.7	1,193
2	Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature, 2014, 514, 47-53.	27.8	883
3	Taxonomy of the order Mononegavirales: update 2016. Archives of Virology, 2016, 161, 2351-2360.	2.1	407
4	Nanozyme-strip for rapid local diagnosis of Ebola. Biosensors and Bioelectronics, 2015, 74, 134-141.	10.1	320
5	Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies. Science Translational Medicine, 2012, 4, 138ra81.	12.4	274
6	Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine. New England Journal of Medicine, 2021, 385, e35.	27.0	244
7	Taxonomy of the order Mononegavirales: update 2019. Archives of Virology, 2019, 164, 1967-1980.	2.1	224
8	VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science, 2015, 349, 739-742.	12.6	213
9	Pre-existing immunity against Ad vectors. Human Vaccines and Immunotherapeutics, 2014, 10, 2875-2884.	3.3	195
10	Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Science Translational Medicine, 2016, 8, 369ra179.	12.4	194
11	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	2.1	184
12	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host and Microbe, 2018, 24, 221-233.e5.	11.0	182
13	Human Adaptation of Ebola Virus during the West African Outbreak. Cell, 2016, 167, 1079-1087.e5.	28.9	180
14	Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17182-17187.	7.1	173
15	Taxonomy of the order Mononegavirales: update 2017. Archives of Virology, 2017, 162, 2493-2504.	2.1	173
16	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	28.9	173
17	Targeted Prostaglandin E2 Inhibition Enhances Antiviral Immunity through Induction of Type I Interferon and Apoptosis in Macrophages. Immunity, 2014, 40, 554-568.	14.3	171
18	Transmission of Ebola Viruses: What We Know and What We Do Not Know. MBio, 2015, 6, e00137.	4.1	169

#	Article	IF	Citations
19	Taxonomy of the order Mononegavirales: update 2018. Archives of Virology, 2018, 163, 2283-2294.	2.1	153
20	Transmission of Ebola virus from pigs to non-human primates. Scientific Reports, 2012, 2, 811.	3.3	149
21	Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates. Science Translational Medicine, 2012, 4, 158ra146.	12.4	135
22	Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology, 2006, 346, 394-401.	2.4	121
23	In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. Npj Vaccines, 2016, 1, 16021.	6.0	118
24	Replication, Pathogenicity, Shedding, and Transmission of Zaire ebolavirus in Pigs. Journal of Infectious Diseases, 2011, 204, 200-208.	4.0	113
25	Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Molecular Therapy, 2003, 8, 777-789.	8.2	105
26	Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine, 2007, 25, 2984-2989.	3.8	102
27	Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus. Scientific Reports, 2014, 4, 6881.	3.3	90
28	DNA vaccination protects mice against Zika virus-induced damage to the testes. Nature Communications, 2017, 8, 15743.	12.8	90
29	Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection. PLoS Neglected Tropical Diseases, 2012, 6, e1575.	3.0	90
30	New filovirus disease classification and nomenclature. Nature Reviews Microbiology, 2019, 17, 261-263.	28.6	84
31	Emergency Postexposure Vaccination With Vesicular Stomatitis Virus–Vectored Ebola Vaccine After Needlestick. JAMA - Journal of the American Medical Association, 2015, 313, 1249.	7.4	82
32	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Reports, 2016, 15, 1514-1526.	6.4	80
33	Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Science Translational Medicine, 2016, 8, 329ra33.	12.4	78
34	Taxonomy of the order Mononegavirales: second update 2018. Archives of Virology, 2019, 164, 1233-1244.	2.1	70
35	Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine, 2007, 25, 5220-5231.	3.8	68
36	Progression of Ebola Therapeutics During the 2014–2015 Outbreak. Trends in Molecular Medicine, 2016, 22, 164-173.	6.7	67

#	Article	IF	Citations
37	Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine, 2014, 32, 5722-5729.	3.8	66
38	Long-Term Correction of Sandhoff Disease Following Intravenous Delivery of rAAV9 to Mouse Neonates. Molecular Therapy, 2015, 23, 414-422.	8.2	64
39	Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease. Journal of Virology, 2016, 90, 9209-9223.	3.4	63
40	Efficacy of Vesicular Stomatitis Virus–Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. Journal of Infectious Diseases, 2016, 214, S360-S366.	4.0	62
41	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	2.1	62
42	MicroRNA and mRNA Dysregulation in Astrocytes Infected with Zika Virus. Viruses, 2017, 9, 297.	3.3	61
43	Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus. Journal of Infectious Diseases, 2010, 201, 1000-1006.	4.0	58
44	Post-exposure therapy of filovirus infections. Trends in Microbiology, 2014, 22, 456-463.	7.7	58
45	Ebolavirus Evolution: Past and Present. PLoS Pathogens, 2015, 11, e1005221.	4.7	58
46	Mucosal Delivery of Adenovirusâ€Based Vaccine Protects against Ebola Virus Infection in Mice. Journal of Infectious Diseases, 2007, 196, S413-S420.	4.0	53
47	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. Viruses, 2014, 6, 3663-3682.	3.3	49
48	A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLoS Neglected Tropical Diseases, 2016, 10, e0004364.	3.0	48
49	Establishment and Characterization of a Lethal Mouse Model for the Angola Strain of Marburg Virus. Journal of Virology, 2014, 88, 12703-12714.	3.4	46
50	Ebola Virus Transmission in Guinea Pigs. Journal of Virology, 2015, 89, 1314-1323.	3.4	46
51	A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. Molecular Pharmaceutics, 2015, 12, 2712-2731.	4.6	46
52	Generation of an adenoviral vaccine vector based on simian adenovirus 21. Journal of General Virology, 2006, 87, 2477-2485.	2.9	46
53	Antibody therapeutics for Ebola virus disease. Current Opinion in Virology, 2016, 17, 45-49.	5.4	45
54	Recent advances in <i>Ebolavirus</i> vaccine development. Hum Vaccin, 2010, 6, 439-449.	2.4	44

#	Article	IF	CITATIONS
55	Backs against the Wall: Novel and Existing Strategies Used during the 2014-2015 Ebola Virus Outbreak. Clinical Microbiology Reviews, 2015, 28, 593-601.	13.6	42
56	PlasmodiumParasitemia Associated With Increased Survival in Ebola Virus–Infected Patients. Clinical Infectious Diseases, 2016, 63, 1026-1033.	5.8	42
57	Development and Characterization of a Guinea Pig-Adapted Sudan Virus. Journal of Virology, 2016, 90, 392-399.	3.4	42
58	Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine, 2014, 32, 2833-2842.	3.8	41
59	Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection. Antiviral Research, 2016, 127, 20-31.	4.1	41
60	Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry. Virology, 2018, 513, 17-28.	2.4	41
61	Personal Protective Equipment for Filovirus Epidemics: A Call for Better Evidence. Journal of Infectious Diseases, 2015, 212, S98-S100.	4.0	40
62	Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory. Scientific Reports, 2014, 4, 5824.	3.3	39
63	The emergence of antibody therapies for Ebola. Human Antibodies, 2015, 23, 49-56.	1.5	37
64	Intramuscular Adeno-Associated Virus–Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice. Journal of Infectious Diseases, 2018, 217, 916-925.	4.0	37
65	Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infectious Diseases, 2015, 15, 432.	2.9	36
66	Human Zika infection induces a reduction of IFN- \hat{I}^3 producing CD4 T-cells and a parallel expansion of effector VÎ 2 T-cells. Scientific Reports, 2017, 7, 6313.	3.3	35
67	From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opinion on Biological Therapy, 2018, 18, 159-173.	3.1	35
68	Nipah Virus Matrix Protein Influences Fusogenicity and Is Essential for Particle Infectivity and Stability. Journal of Virology, 2016, 90, 2514-2522.	3.4	34
69	Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Scientific Reports, 2016, 6, 24179.	3.3	33
70	Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. Journal of Virology, 2016, 90, 7618-7627.	3.4	32
71	Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination. Scientific Reports, 2017, 7, 43776.	3.3	31
72	Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. Journal of Infectious Diseases, 2016, 214, S281-S289.	4.0	30

#	Article	IF	Citations
73	Plant-made vaccines and therapeutics. Science, 2021, 373, 740-741.	12.6	27
74	Human Immunodeficiency Viral Vector Pseudotyped with the Spike Envelope of Severe Acute Respiratory Syndrome Coronavirus Transduces Human Airway Epithelial Cells and Dendritic Cells. Human Gene Therapy, 2007, 18, 413-422.	2.7	26
75	Syrian Hamsters as a Small Animal Model for Emerging Infectious Diseases: Advances in Immunologic Methods. Advances in Experimental Medicine and Biology, 2016, 972, 87-101.	1.6	24
76	Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014–2015. Journal of Infectious Diseases, 2016, 214, S169-S176.	4.0	24
77	Novel Adeno-associated Viruses Derived From Pig Tissues Transduce Most Major Organs in Mice. Scientific Reports, 2014, 4, 6644.	3.3	23
78	Pandemic Swine-Origin H1N1 Influenza Virus Replicates to Higher Levels and Induces More Fever and Acute Inflammatory Cytokines in Cynomolgus versus Rhesus Monkeys and Can Replicate in Common Marmosets. PLoS ONE, 2015, 10, e0126132.	2.5	22
79	Successful Control of Ebola Virus Disease: Analysis of Service Based Data from Rural Sierra Leone. PLoS Neglected Tropical Diseases, 2016, 10, e0004498.	3.0	22
80	Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses. Viruses, 2017, 9, 106.	3.3	22
81	Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. Journal of Infectious Diseases, 2018, 218, S553-S564.	4.0	22
82	The ongoing evolution of antibody-based treatments for Ebola virus infection. Immunotherapy, 2017, 9, 435-450.	2.0	20
83	Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. AIDS Research and Therapy, 2017, 14, 55.	1.7	20
84	The Cellular Impact of the ZIKA Virus on Male Reproductive Tract Immunology and Physiology. Cells, 2020, 9, 1006.	4.1	20
85	Fluorescent Crimean-Congo hemorrhagic fever virus illuminates tissue tropism patterns and identifies early mononuclear phagocytic cell targets in Ifnar-/- mice. PLoS Pathogens, 2019, 15, e1008183.	4.7	19
86	Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study. Journal of Infectious Diseases, 2015, 212, S389-S397.	4.0	18
87	Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus–Infected Nonhuman Primates. Journal of Infectious Diseases, 2015, 212, S379-S383.	4.0	18
88	Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine. Vaccine, 2018, 36, 3079-3089.	3.8	18
89	Development and Characterization of a Sin Nombre Virus Transmission Model in Peromyscus maniculatus. Viruses, 2019, 11, 183.	3.3	18
90	Living with the COVID-19 pandemic: act now with the tools we have. Lancet, The, 2020, 396, 1314-1316.	13.7	18

#	Article	IF	CITATIONS
91	Dual RNA-Seq characterization of host and pathogen gene expression in liver cells infected with Crimean-Congo Hemorrhagic Fever Virus. PLoS Neglected Tropical Diseases, 2020, 14, e0008105.	3.0	18
92	Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Antiviral Research, 2015, 116, 17-19.	4.1	17
93	Possibility and Challenges of Conversion of Current Virus Species Names to Linnaean Binomials. Systematic Biology, 2016, 66, syw096.	5.6	17
94	Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends in Molecular Medicine, 2017, 23, 820-830.	6.7	17
95	Zika Virus Vaccines: Challenges and Perspectives. Vaccines, 2018, 6, 62.	4.4	17
96	Modeling Ebola Virus Transmission Using Ferrets. MSphere, 2018, 3, .	2.9	16
97	Antibody therapy for Ebola. Human Vaccines and Immunotherapeutics, 2014, 10, 964-967.	3.3	15
98	More Challenges From Ebola: Infection of the Central Nervous System. Journal of Infectious Diseases, 2016, 214, S294-S296.	4.0	15
99	Adeno-Associated Virus Serotype 9-Expressed ZMapp in Mice Confers Protection Against Systemic and Airway-Acquired Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, 1975-1979.	4.0	14
100	Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time. Scientific Reports, 2017, 7, 3390.	3.3	14
101	Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient. PLoS Pathogens, 2017, 13, e1006065.	4.7	14
102	Essentials of filoviral load quantification. Lancet Infectious Diseases, The, 2016, 16, e134-e138.	9.1	13
103	NK Cells Accumulate in Infected Tissues and Contribute to Pathogenicity of Ebola Virus in Mice. Journal of Virology, 2019, 93, .	3.4	13
104	The Makona Variant of Ebola Virus Is Highly Lethal to Immunocompromised Mice and Immunocompetent Ferrets. Journal of Infectious Diseases, 2018, 218, S466-S470.	4.0	12
105	Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses. PLoS ONE, 2019, 14, e0216949.	2.5	12
106	Altered microRNA Transcriptome in Cultured Human Liver Cells upon Infection with Ebola Virus. International Journal of Molecular Sciences, 2021, 22, 3792.	4.1	12
107	Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1. Journal of Virology, 2021, 95, e0236820.	3.4	12
108	Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Scientific Reports, 2016, 6, 30497.	3.3	11

#	Article	IF	Citations
109	Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans. Antiviral Research, 2016, 126, 55-61.	4.1	11
110	Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. Journal of Infectious Diseases, 2019, 219, 365-374.	4.0	11
111	Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model. Intensive Care Medicine Experimental, 2019, 7, 54.	1.9	11
112	Hantavirus Cardiopulmonary Syndrome in Canada. Emerging Infectious Diseases, 2020, 26, 3020-3024.	4.3	10
113	Vaccine innovation spurred by the long wait for an Ebola virus vaccine. Lancet Infectious Diseases, The, 2021, 21, 440-441.	9.1	10
114	Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice. Journal of Infectious Diseases, 2015, 212, S435-S442.	4.0	9
115	Diagnosis and management of Ebola samples in the laboratory. Expert Review of Anti-Infective Therapy, 2016, 14, 557-567.	4.4	9
116	Baited vaccines: A strategy to mitigate rodentâ€borne viral zoonoses in humans. Zoonoses and Public Health, 2018, 65, 711-727.	2.2	9
117	R88-APOBEC3Gm Inhibits the Replication of Both Drug-resistant Strains of HIV-1 and Viruses Produced From Latently Infected Cells. Molecular Therapy - Nucleic Acids, 2014, 3, e151.	5.1	8
118	Challenges and perspectives on the use of mobile laboratories during outbreaks and their use for vaccine evaluation. Human Vaccines and Immunotherapeutics, 2019, 15, 2264-2268.	3.3	8
119	Oral Vaccination With Recombinant Vesicular Stomatitis Virus Expressing Sin Nombre Virus Glycoprotein Prevents Sin Nombre Virus Transmission in Deer Mice. Frontiers in Cellular and Infection Microbiology, 2020, 10, 333.	3.9	7
120	Vaccines against â€~the other' <i>Ebolavirus</i> species. Expert Review of Vaccines, 2016, 15, 1093-1100.	4.4	6
121	Diagnostic strategies for Ebola virus detection. Lancet Infectious Diseases, The, 2016, 16, 294-295.	9.1	6
122	Consequences of Pathogen Lists: Why Some Diseases May Continue to Plague Us. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1052-1055.	1.4	5
123	Modeling host-feeding preference and molecular systematics of mosquitoes in different ecological niches in Canada. Acta Tropica, 2021, 213, 105734.	2.0	4
124	Computational genomics of Torque teno sus virus and Porcine circovirus in swine samples from Canada. Research in Veterinary Science, 2021, 134, 171-180.	1.9	4
125	Ebola virus is unlikely to become endemic in West Africa. Nature Microbiology, 2016, 1, 16007.	13.3	3
126	Therapeutics Against Filovirus Infection. Current Topics in Microbiology and Immunology, 2017, 411, 263-290.	1.1	3

#	Article	IF	CITATIONS
127	How to turn competitors into collaborators. Nature, 2017, 541, 283-285.	27.8	3
128	Empowerment of Women: Closing the Medical Technologies Gender Gap. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 78-83.	0.7	3
129	Contribution of Environment Sample-Based Detection to Ebola Outbreak Management. Journal of Infectious Diseases, 2018, 218, S292-S296.	4.0	3
130	Safety and immunogenicity of vesicular stomatitis virus-based vaccines for Ebola virus disease. Lancet Infectious Diseases, The, 2020, 20, 388-389.	9.1	3
131	A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity. Vaccine, 2021, 39, 7175-7181.	3.8	3
132	Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection. Methods in Molecular Biology, 2017, 1628, 273-282.	0.9	2
133	Experimental countermeasures against Ebola virus: current progress and an ethical conundrum. Cmaj, 2014, 186, 1129-1130.	2.0	1
134	Testing Experimental Therapies in a Guinea Pig Model for Hemorrhagic Fever. Methods in Molecular Biology, 2018, 1604, 269-278.	0.9	1
135	Increased mortality in survivors of Ebola virus disease. Lancet Infectious Diseases, The, 2019, 19, 1152-1154.	9.1	1
136	OUP accepted manuscript. Journal of Infectious Diseases, 2021, , .	4.0	1
137	Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia. Journal of Infectious Diseases, 2022, 225, 1852-1855.	4.0	1
138	Longitudinal Analysis of SIVmac239 Mutations around the 12 Protease Cleavage Sites and their Correlations with Viral Load Reduction and CD4 counts. AIDS Research and Human Retroviruses, 2014, 30, A245-A246.	1.1	0
139	Sequences Surrounding the 12 Protease Cleavage Sites are Good Targets for Both Prophylactic and Therapeutic HIV Vaccines. AIDS Research and Human Retroviruses, 2014, 30, A246-A246.	1.1	0
140	Overlooking the importance of immunoassays – Authors' reply. Lancet Infectious Diseases, The, 2016, 16, 1110.	9.1	0
141	Reply to Reisler et al. Clinical Infectious Diseases, 2018, 66, 1480-1481.	5.8	0
142	In vivo generation of collagen specific Tregs with AAV8 suppresses autoimmune responses and arthritisÂin DBA1 miceÂthrough IL10 production. Scientific Reports, 2021, 11, 18204.	3.3	О